RBM3 and neoplasm: PFS was longer for patients with tumours displaying high nuclear or cytoplasmic RBM3 expression who received oxaliplatin based treatment as first-line chemotherapy, in comparison to irinotecan based treatment (p-value 0.020 for nuclear expression and 0.022 for cytoplasmic expression).